HB 1566-FN (2022): relative to the New Hampshire prescription drug affordability board.
Cite this page
Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.
- MLA
- “HB 1566-FN (2022): relative to the New Hampshire prescription drug affordability board.” Granite Record, https://graniterecord.org/bill/2022/hb1566. Accessed 24 Oct. 2026.
- APA
- Granite Record. (n.d.). HB 1566-FN (2022): relative to the New Hampshire prescription drug affordability board. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2022/hb1566
- Chicago
- Granite Record. “HB 1566-FN (2022): relative to the New Hampshire prescription drug affordability board.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2022/hb1566.
- BibTeX
@misc{bill-2022-hb1566, title = {HB 1566-FN (2022): relative to the New Hampshire prescription drug affordability board.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2022/hb1566}, note = {Accessed 24 Oct. 2026} }
HB 1566-FN (2022)
relative to the New Hampshire prescription drug affordability board.
- Status: Referred for interim study
- Term: 2021-2022
- House committee: Executive Departments and Administration
- Subject: Public and Mental Health
The Story
It was introduced on January 5, 2022 and referred to the House Executive Departments and Administration committee. The committee held a work session on January 28, 2022. The committee met in executive session on February 8, 2022 to vote on its recommendation. The committee voted unanimously, 19–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On February 16, 2022 the House voted to study it after the session ends on a voice vote. The committee held a work session on May 24, 2022. The committee met in executive session on October 5, 2022 to vote on its recommendation. The committee reported back on its interim study of the bill: “Not Recommended for Future Legislation”, by a vote of 14 to 0.
Sponsors
- Rep. James Murphy (D - Graf 12) (prime sponsor)
- Rep. William Marsh (D - Carr 8)
- Rep. Gary Merchant (D - Sull 4)
- Rep. Joyce Weston (D - Graf 8)
- Sen. Tom Sherman (D - SD24)
- Sen. Sharon Carson (R - SD14)
Hearings and Sessions
- January 11, 2022, 9:45 AM: public hearing, House Executive Departments and Administration, LOB302-304
- January 28, 2022, 1:00 PM: subcommittee work session, House Executive Departments and Administration, LOB 302-304
- February 8, 2022, 3:00 PM: public hearing, House Executive Departments and Administration, LOB302-304
- February 8, 2022, 3:00 PM: executive session, House Executive Departments and Administration, LOB302-304
- May 24, 2022, 10:30 AM: work session, House Executive Departments and Administration, LOB 302-304
- October 5, 2022, 1:00 PM: executive session, House Executive Departments and Administration, LOB 302-304
Votes
- February 16, 2022, House: Refer for Interim Study — voice vote, passed
The Docket
- January 5, 2022: Introduced 01/05/2022 and referred to Executive Departments and Administration
- January 11, 2022: Public Hearing: 01/11/2022 9:45 a.m. LOB302-304
- January 28, 2022: Subcommittee Work Session: 01/28/2022 01:00 pm LOB 302-304
- February 3, 2022: Public Hearing on Amendment #2022-0375h : 02/08/2022 03:00 PM LOB302-304
- February 8, 2022: Public Hearing: 02/08/2022 3:00 p.m. LOB302-304
- February 8, 2022: Executive Session: 02/08/2022 03:00 pm LOB302-304
- February 9, 2022: Committee Report: Refer for Interim Study (Vote 19-0; CC)
- February 16, 2022: Refer for Interim Study: MA VV 02/16/2022
- May 24, 2022: Interim Study Work Session: 05/24/2022 10:30 am LOB 302-304
- October 5, 2022: Executive Session: 10/05/2022 01:00 pm LOB 302-304
- October 26, 2022: Interim Study Report: Not Recommended for Future Legislation (Vote 14-0)